New Phase 2 Data for Somapacitan Demonstrate Its Potential as ...
ATHENS, Greece, Sept. 28, 2018 /PRNewswire-AsiaNet/ -- Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin(R) (somatropin) in a phase 2 trial in children with growth hormone defi...
Read more https://view-release/?pr-id=75471